Melinta presents positive Phase III data supporting Vabomere

28 February 2018

East Coast, USA-based Melinta Therapeutics (Nasdaq: MLNT) has published positive results from the Phase III TANGO I study of Vabomere (meropenem and vaborbactam).

The injectable antibiotic was approved by the US Food and Drug Administration (FDA) in August 2017 as a treatment for certain complicated urinary tract infections (cUTI).

The TANGO I trial, which compared efficacy and safety with piperacillin-tazobactam in this patient population, found Vabomere was non-inferior with overall success in 98.4% of treated patients compared with 94% following treatment with piperacillin-tazobactam.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK